KLSE (MYR): ALPHA (0303)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.335
Today's Change
0.00 (0.00%)
Day's Change
0.33 - 0.335
Trading Volume
1,010,500
Market Cap
1,628 Million
NOSH
4,860 Million
Latest Quarter
31-Aug-2024 [#1]
Announcement Date
21-Oct-2024
Next Quarter
30-Nov-2024
Est. Ann. Date
18-Mar-2025
Est. Ann. Due Date
29-Jan-2025
QoQ | YoY
2.66% | 0.00%
Revenue | NP to SH
168,985.000 | 54,192.000
RPS | P/RPS
3.48 Cent | 9.63
EPS | P/E | EY
1.12 Cent | 30.04 | 3.33%
DPS | DY | Payout %
1.10 Cent | 3.28% | 98.43%
NAPS | P/NAPS
0.04 | 8.38
QoQ | YoY
36.12% | null%
NP Margin | ROE
32.84% | 27.88%
F.Y. | Ann. Date
31-Aug-2024 | 21-Oct-2024
Latest Audited Result
31-May-2024
Announcement Date
30-Sep-2024
Next Audited Result
31-May-2025
Est. Ann. Date
30-Sep-2025
Est. Ann. Due Date
27-Nov-2025
Revenue | NP to SH
167,586.000 | 52,933.000
RPS | P/RPS
3.45 Cent | 9.72
EPS | P/E | EY
1.15 Cent | 30.76 | 3.25%
DPS | DY | Payout %
0.70 Cent | 2.09% | 64.27%
NAPS | P/NAPS
0.04 | 8.38
YoY
null%
NP Margin | ROE
32.26% | 27.23%
F.Y. | Ann. Date
31-May-2024 | 17-Jul-2024
Revenue | NP to SH
171,980.000 | 57,524.000
RPS | P/RPS
3.54 Cent | 9.47
EPS | P/E | EY
1.20 Cent | 28.30 | 3.53%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
8.67% | null%
NP Margin | ROE
34.76% | 29.59%
F.Y. | Ann. Date
31-Aug-2024 | 21-Oct-2024
Trailing 4 Quarters | Trailing 8 Quarters | |||
---|---|---|---|---|
Available Quarters | 4 Quarters | 8 Quarters | ||
Continuous Quarters Of Revenue Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Total Positive Profit Years | 4 / 4 | 100.00% | 4 / 8 | 50.00% |
Continuous Quarters Of Positive Profit | 4 / 4 | 100.00% | 4 / 8 | 50.00% |
Continuous Quarters Of Profit Growth | 4 / 4 | 100.00% | 4 / 8 | 50.00% |
Continuous Quarters Of Adjusted EPS Growth | 4 / 4 | 100.00% | 4 / 8 | 50.00% |
Total Dividend Years | 3 / 4 | 75.00% | 3 / 8 | 38.00% |
Continuous Quarters Of Dividend | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Average ROE | 14.61% | 7.30% | ||
Average Net Profit Margin | 32.89% | 16.44% |
Last 5 Financial Years | Last 10 Financial Years | |||
---|---|---|---|---|
Available Years | 5 Years | 10 Years | ||
Continuous Quarters Of Revenue Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Total Positive Profit Years | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Positive Profit | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Profit Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Adjusted EPS Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Total Dividend Years | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Dividend | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Dividend Growth | 0 / 2 | 0.00% | 0 / 2 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Average ROE | 13.62% | 13.62% | ||
Average Net Profit Margin | 16.13% | 16.13% |
T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
---|---|---|---|---|---|
Revenue | 168,985 | 171,980 | 167,586 | 83,793 | 83,793 |
NP to SH | 54,192 | 57,524 | 52,933 | 26,466 | 26,466 |
Dividend | 53,338 | 87,479 | 34,019 | 17,009 | 17,009 |
Adjusted EPS | 1.12 | 1.20 | 1.15 | 0.58 | 0.58 |
Adjusted DPS | 1.10 | 1.80 | 0.70 | 0.35 | 0.35 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
---|---|---|---|---|---|
Revenue | -8.02% | 0.00% | 0.00% | 1.77% | 103.54% |
NP to Owner | 2.66% | 0.00% | 0.00% | 6.15% | 112.30% |
Dividend | 0.00% | 0.00% | 0.00% | 64.01% | 228.02% |
Adjusted EPS | 3.45% | 0.00% | 0.00% | 7.06% | 114.11% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 64.01% | 228.02% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.83% | 101.67% | 101.67% | 2.62% | 105.24% | 105.24% | 0.00% | 100.00% | 100.00% |
NP to Owner | 2.38% | 104.76% | 104.76% | 8.67% | 117.35% | 117.35% | 0.00% | 100.00% | 100.00% |
Dividend | 56.79% | 213.57% | 213.57% | 157.14% | 414.29% | 414.29% | 0.00% | 100.00% | 100.00% |
Adjusted EPS | -2.61% | 94.78% | 94.78% | 4.35% | 108.70% | 108.70% | 0.00% | 100.00% | 100.00% |
Adjusted DPS | 57.14% | 214.29% | 214.29% | 157.14% | 414.29% | 414.29% | 0.00% | 100.00% | 100.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Buying volume is healthy and momentum is good. Just wait for the upcoming soar 😌
2 weeks ago
Chill lah, ALPHA operates in a highly specialized field with stringent regulatory requirements, creating significant barriers to entry and protecting its market share. The potential return is promising, just the matter of time only.
2 weeks ago
ALPHA’s strategic presence in Malaysia, with proximity to key Asian markets, positions it to capitalize on the region’s growing demand for advanced reproductive healthcare.
2 weeks ago
Dividend is here - ALPHA IVF GROUP BERHAD declared Interim Dividend - RM 0.0050, the Ex Date on 17-Dec-2024.
2 weeks ago
No wonder directors have been buying a lot recently. I will continue to chip in to enjoy this dividend 😋
2 weeks ago
Constantly giving out dividend, will it attract more income investors and push the price up?
2 weeks ago
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3506133
The 0.5 sen per share interim dividend is a positive development for both shareholders and the company. This reflect the company's commitment to sharing profits with shareholders and signaling strong financial health
2 weeks ago
The worldwide fertility rates is declining, so they are perfectly positioned to capitalize on the increasing demand for IVF services. Much growth potential in this counter
2 weeks ago
Fib retracement at a nice zone and there is sign of divergence, good time to whack some.
2 weeks ago
ALPHA is killing it with all the latest tech in IVF treatments. They’re ahead of the game, which is a huge plus for investors.
1 week ago
From Aminvest -Retain BUY on Alpha IVF with unchanged FV of RM0.42, based on 28x CY25 PE. We attach a 3-star ESG rating to Alpha IVF. Our earnings forecast remains unchanged as the Group's 1QFY25 core net profit tracking expectation at 21.3% of our full year estimates.
1 week ago
ALPHA’s success rates in IVF are no joke among the industry players. Strong selling point for patients and investors like us.
1 week ago
They offers additional Assisted Reproductive Technology (ART) services too, such as ICSI, IUI, diagnostics, testing, screening procedures, and cryopreservation of eggs, sperm, and embryos.
1 week ago
Healthcare doesn’t slow down, even during tough times. ALPHA’s in a pretty safe spot, which is a huge bonus for long-term investors.
1 week ago
ALPHA is slowly becoming a recognized name, not just locally but internationally. That kind of growth potential is exciting.
1 week ago
+1 here. I will slowly build up my Alpha stock position
NorAfan
Masuk lagi semasa dapat dividen pd 31 Dec 🙂
2 days ago
1 week ago
Keep top up Alpha, where the comapny has a dividend policy which plans to pay out a minimum of 60% of its earnings as dividends, translating to a 2.3% dividend yield in FY24.
1 week ago
The fertility industry is growing like crazy worldwide, and ALPHA is positioned to grab a nice slice of that pie.
1 week ago
There is a bright future in expanding the markets in China, Indonesia and the Philippines 👍
6 days ago
ALPHA isn’t just serving Malaysia anymore, they’re steadily building a name across Southeast Asia. Big growth potential here
5 days ago
ALPHA will be the SEA regional leader in fertility care with more expansion into Indonesia and the Philippines, stay for the long term growth & dividend
4 days ago
They’ve got some of the most advanced tech in IVF treatments. That edge keeps them ahead of competitors.
4 days ago
With fertility awareness growing in underdeveloped regions, ALPHA has the opportunity to be a pioneer in those markets.
3 days ago
Not only that, genetic testing is becoming more popular in IVF, their expertise in this area will definitely drive future growth.
2 days ago
NOSH is too high in the market! For it to move, it really needs a very high volume trade. DY will be low too, unless the revenue and margin grow significantly.
2 days ago
YTL Power's NOSH is also high. We just need to wait for ALPHA's turn to be goreng up 😁
2 days ago
sweetpie
ALPHA collaborates with international experts and institutions, bringing global best practices to their patients. This makes them a trusted name in the field of reproductive medicine.
3 weeks ago